You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 47 No. 3, March 1990 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL CONTRIBUTIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (50)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Comparison of the Neuroprotective Effects of the N-Methyl-D-Aspartate Antagonist MK-801 and the Opiate-Receptor Antagonist Nalmefene in Experimental Spinal Cord Ischemia

Sabrina W. Yum, MD; Alan I. Faden, MD

Arch Neurol. 1990;47(3):277-281.


Abstract



• Both N-methyl-D-aspartate (NMDA)-receptor antagonists and opiate-receptor antagonists have been shown to limit tissue damage after ischemic central nervous system injury. We compared the neuroprotective effects of the noncompetitive NMDA-receptor antagonist MK-801 and the opiate-receptor antagonist nalmefene in a model of global spinal cord ischemia and reperfusion in unanesthetized rabbits. MK-801 (1 mg/kg) or nalmefene (0.1 mg/kg) was administered intravenously 5 minutes after reperfusion. MK-801 treatment and nalmefene treatment each significantly improved the neurologic and histologic outcome compared with saline controls. Differences in these outcome measures between MK-801 treatment and nalmefene treatment did not reach statistical significance. Our results are consistent with the hypothesis that multiple factors, including endogenous opioids and excitatory amino acids, contribute to the secondary tissue injury after central nervous system ischemia. These data also provide further evidence that therapeutic interventions with opiate-receptor antagonists or NMDA antagonists may be beneficial in limiting neurologic dysfunction after ischemic brain or spinal cord injury.



Author Affiliations



From the Center for Neural Injury, Department of Neurology, University of California, San Francisco, and the Department of Veterans Affairs, San Francisco.


Footnotes



Accepted for publication July 11, 1989.

Reprint requests to the Neurology Service (127), Department of Veterans Affairs, 4150 Clement St, San Francisco, CA 94121 (Dr Faden).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Retrograde perfusion with a sodium channel antagonist provides ischemic spinal cord protection
Gangemi et al.
Ann. Thorac. Surg. 2000;69:1744-1748.
ABSTRACT | FULL TEXT  

Cervene (Nalmefene) in Acute Ischemic Stroke : Final Results of a Phase III Efficacy Study
Clark et al.
Stroke 2000;31:1234-1239.
ABSTRACT | FULL TEXT  

Selective protection of gray and white matter during spinal cord ischemic injury
Follis et al.
Ann. Thorac. Surg. 1999;67:1362-1369.
ABSTRACT | FULL TEXT  

Prevention of spinal cord injury after repair of the thoracic or thoracoabdominal aorta
Mauney et al.
Ann. Thorac. Surg. 1995;59:245-252.
ABSTRACT  

Spinal cord protection during aortic occlusion: Efficacy of intrathecal tetracaine
Breckwoldt et al.
Ann. Thorac. Surg. 1991;51:959-963.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.